Skip to main content
. 2020 Sep 25;14:3941–3950. doi: 10.2147/DDDT.S271008

Table 3.

Changes of Joint Mobility and Pain Level of Patient with DF After Anlotinib Treatment

Patients Tumor Site Involved Joint RECIST 1.1
Response
Pre/Post-Treated Pain Level (VAS) Pre/Post-Treated Range of Motion (°)
Flexion Extension Abduction Adduction External Rotation Internal Rotation
1 Upper arm Elbow PR 4/2 90/120 0/0 NA NA NA NA
2 Gluteal region Hip SD 5/3 60/60 5/0 30/20 20/20 30/30 40/40
3 Thigh Hip PD 5/4 15/NA 0/NA 20/NA 5/NA 40/NA 40/NA
4 Popliteal region Knee SD 5/3 50/90 20/15 NA NA 30/30 10/10
5 Hand MCP joint PR 6/1 30/70 5/30 NA NA NA NA
6 Forearm Wrist SD 6/2 20/50 10/30 NA NA 25/50a 40/60b
7 Gluteal region Hip PR 5/3 60/90 0/10 15/20 10/20 30/40 30/40
8 Gluteal region Hip SD 6/1 90/130 10/20 10/30 20/20 40/40 40/40
9 Upper arm Elbow PR 7/1 60/110 10/0 NA NA NA NA
10 Hand MCP joint SD 4/3 40/60 10/20 NA NA NA NA
11 Upper arm Elbow SD 3/0 80/120 20/5 NA NA NA NA
12 Popliteal region Knee SD 6/2 90/130 10/0 NA NA 30/30 10/10
13 Upper arm Elbow PR 3/0 110/130 10/5 NA NA NA NA
14 Upper arm Elbow PR 7/1 60/130 5/0 NA NA NA NA
15 Thigh Knee PD 4/3 60/NA 10/NA NA NA 30/NA 10/NA
16 Gluteal region Hip SD 3/1 100/100 10/10 10/10 20/20 40/40 40/40
17 Scapular region Shoulder PR 6/2 50/90 20/40 30/60 10/40 40/60 50/70
18 Foot MTP joint PD 5/6 20/NA 15/NA NA NA NA NA
19 Scapular region Shoulder SD 6/3 70/70 10/10 20/20 20/20 30/30 70/70
20 Upper arm Elbow PR 5/1 90/110 30/10 NA NA NA NA
21 Axillary region Shoulder SD 4/2 90/90 30/40 40/50 30/30 10/20 30/40

Notes: aMeans range of pronation. bMeans range of supination.

Abbreviations: NA, not achieved, MCP, metacarpophalangeal; MTP, metatarsophalangeal.